Pharmacoepidemiology of antidepressants in the Russian Federation
https://doi.org/10.37489/2782-3784-myrwd-068
EDN: VZWAZD
Abstract
Objective. To assess the volume and structure dynamics of antidepressant consumption in the Russian Federation (RF).
Materials and methods. Data on the sales of medicines belonging to the ATX class N06A (antidepressants) were downloaded from the IQVIA database in the period 2019–2024. Selected those mentioned in the current Russian clinical guidelines for use in patients with neurotic, stress-related and somatoform disorders (ICD code F40‑F48). The estimated number of patients who received a one-year course of antidepressants, as well as the number of DDDs/1000 inhabitants per day in each of the follow-up years, was calculated.
Results. In the period 2019–2024, sales of antidepressants more than doubled in the RF: 200 million were sold in 2019, while about 500 million DDDs in 2024, which corresponds to 3.8 in 2019 and 9.4 DDDs/1000 inhabitants per day in 2024. The estimated number of patients who received a one-year course of antidepressants increased from 570,000 in 2019 to 1.38 million in 2024. The predominant sales channel throughout the observation period was retail sales, which accounted for 84 % in 2019 to 94 % in 2024 of the total sales in each of the observation years. SSRIs (primarily sertraline and escitalopram) accounted for most sales (up to 75 %) throughout the follow-up. Regional sales correlated with the size of the region’s population.
Conclusions. The expansion of the practice of using antidepressants in the RF requires careful collection of safety data both as part of the analysis of the national Pharmacovigilance database and as part of real clinical practice research.
About the Authors
Yu. M. Gomon
First St. Petersburg State Medical University named after I. P. Pavlov
Russian Federation
Competing Interests:
Russian Federation
Yulia M. Gomon — Dr. Sci. (Med.), professor of the department of Clinical Pharmacology and Evidence-Based Medicine
Competing Interests:
The authors declare no conflict of interest.
A. S. Kolbin
First St. Petersburg State Medical University named after I. P. Pavlov; St. Petersburg State University
Russian Federation
Competing Interests:
Russian Federation
Alexey S. Kolbin –– Dr. Sci. (Med.), Professor, Head. Department of Clinical Pharmacology and Evidence-Based Medicine; Professor of the Department of Pharmacology, Faculty of Medicine
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
V. A. Lavrova
First St. Petersburg State Medical University named after I. P. Pavlov
Russian Federation
Competing Interests:
Russian Federation
Victoria A. Lavrova –– Cand. Sci. (Med.), Assistant Professor at the Department of Psychiatry and Narcology
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
N. G. Neznanov
First St. Petersburg State Medical University named after I. P. Pavlov; V. M. Bekhterev National Research Medical Center of Psychiatry and Neurology
Russian Federation
Competing Interests:
Russian Federation
Nikolay G. Neznanov –– Dr. Sci. (Med.), Professor, Head of the Department of Psychiatry and Narcology; Director
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
References
1. Arias D, Saxena S, Verguet S. Quantifying the global burden of mental disorders and their economic value. EClinicalMedicine. 2022;54:101675. doi: 10.1016/j.eclinm.2022.101675.
2. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022 Feb;9(2):137-150. doi: 10.1016/S2215-0366(21)00395-3.
3. Russian clinical guidelines.
4. American Psychological Association (2019) Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline.
5. NICE (2020) Generalised anxiety disorder and panic disorder in adults: management. https://www.nice.org.uk/guidance/cg113.
6. Lunghi C, Dugas M, Lecrlerc J, et al. Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review. BMJ open e. 2022;062197:12. doi: 10.1136/bm-jopen-2022-062197.
7. Wong J, Motulsky A, Eguale T, et al. Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006–2015. JAMA. 2016;20(315):2230–2232. doi: 10.1001/jama.2016.3445.
8. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655–79.
9. McManus S, Meltzer H, Brugha T, Bebbington P, Jenkins R (eds). Adult Psychiatric Morbidity in England, 2007: Results of a Household Survey. NHS Information Centre for Health and Social Care, 2009.
10. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 357–76.
11. Hengartner MP (2022) Evidence-biased antidepressant prescription. Overmedicalisation, flawed research, and conflicts of interest. Springer International Publishing, Cham
12. Evans-Lacko S, Brohan E, Mojtabai R, Thornicroft G. Association between public views of mental illness and self-stigma among individuals with mental illness in 14 European countries. Psychol Med 2012; 42: 1741–52.
13. Mojtabai R. Mental illness stigma and willingness to seek mental health care in the European Union. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 705–12.
14. Lewer D, O’Reilly C, Mojtabai R, Evans-Lacko S. Antidepressant use in 27 European countries: Associations with sociodemographic, cultural and economic factors. British Journal of Psychiatry. 2015;207(03):221–226. doi:10.1192/bjp.bp.114.156786.
15. Solmi M, Miola A, Croatto G, et al. How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Braz J Psychiatry. 2021 Mar-Apr;43(2):189-202. Doi: 10.1590/1516-4446-2020-0935.
16. Resolution of the Government of the Russian Federation of July 30, 1994 No. 890 "On state support for the development of the medical industry and improving the provision of the population and healthcare institutions with medicines and medical products" with amendments from February 14, 2002..
17. WHO Collaborating Centre for Drug Statistics Methodology. https://atcddd.fhi.no/
18. Population of the Russian Federation by municipalities as of January 1, 2024.
19. Marasine NR, Sankhi S, Lamichhane R, et al. Use of Antidepressants among Patients Diagnosed with Depression: A Scoping Review. Biomed Res Int. 2021 Mar 15;2021:6699028. doi: 10.1155/2021/6699028.
20. Cebron Lipovec N, Anderlic A, Locatelli I. General antidepressants prescribing trends 2009-2018 in Slovenia: a cross-sectional retrospective database study. Int J Psychiatry Clin Pract. 2022 Nov;26(4):401-405. doi: 10.1080/13651501.2022.2057331.
21. Heald AH, Stedman M, Davies M, et al. Antidepressant Prescribing in England: Patterns and Costs. Prim Care Companion CNS Disord. 2020 Apr 16;22(2):19m02552. doi: 10.4088/PCC.19m02552.
22. Yu Z, Zhang J, Zheng Y, Yu L. Trends in Antidepressant Use and Expenditure in Six Major Cities in China From 2013 to 2018. Front Psychiatry. 2020 Jul 16;11:551. doi: 10.3389/fp-syt.2020.00551.
23. McCool A, Lukas K, Hayes P, Kelly D. Antidepressant medication prescribing patterns in Irish general practice from 2016 to 2020 to assess for long-term use. Ir J Med Sci. 2022 Oct;191(5):2239-2246. doi: 10.1007/s11845-021-02833-7.
24. Brauer R, Alfageh B, Blais JE, et al. Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study. Lancet Psychiatry. 2021 Dec;8(12):1071-1082. doi: 10.1016/S2215-0366(21)00292-3.
25. Kendrick T. Strategies to reduce use of antidepressants. Br J Clin Pharmacol. 2021;87(1):23–33. doi: 10.1111/bcp.14475.
26. Lunghi C, Antonazzo IC, Burato S, et al. Prevalence and determinants of long-term utilization of antidepressant drugs: a retrospective cohort study. Neuropsychiatr Dis Treat. 2020;16:1157–1170. doi: 10.2147/NDT.S241780.
27. Verhaak PFM, de Beurs D, Spreeuwenberg P. What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis. BMJ open. 2019;9(2):e024051. doi: 10.1136/bmjopen-2018-024051.
28. Huijbregts KM, Hoogendoorn A, Slottje P, van Balkom AJLM, Batelaan NM. Long-term and short-term antidepressant use in general practice: data from a large cohort in the Netherlands. Psychother Psychosom. 2017;86(6):362–369. doi: 10.1159/000480456.
29. Camacho-Arteaga LF, Gardarsdottir H, Ibañez L, et al. Indications related to antidepressant prescribing in the Nivel-PCD database and the SIDIAP database. J Affect Disord. 2022 Apr 15;303:131-137. doi: 10.1016/j.jad.2022.02.001.
30. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7
31. Tan B, Chen L, Yan S, et al. Risk of stress cardiomyopathy associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors: a real-world pharmacovigilance analysis. Sci Rep. 2024 Jul 2;14(1):15167. doi: 10.1038/s41598-024-66155-1.
32. Wang Y, Lin Y, Lin Q, et al. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database. Sci Rep. 2023 Jul 28;13 (1):12257. doi: 10.1038/s41598-023-39482-y.
33. Dobrea CM, Frum A, Butuca A, et al. Drug-Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database. Pharmaceuticals (Basel). 2024 Sep 26;17(10):1278. doi: 10.3390/ph17101278.
34. de Filippis R, Mercurio M, Spina G, et al. Antidepressants and Vertebral and Hip Risk Fracture: An Updated Systematic Review and Meta-Analysis. Healthcare (Basel). 2022 Apr 26;10(5):803. doi: 10.3390/healthcare10050803.
35. Minoc EM, Villain C, Benbrika S, et al. Association between antidepressant use and delirium in older adults: an analysis of the World Health Organization's global pharmacovigilance database. BMC Geriatr. 2024 Jul 12;24(1):600. doi: 10.1186/s12877-024-05022-0.
36. Makady A, van Veelen A, Jonsson P, et al. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. Pharmacoeconomics. 2018 Mar;36 (3):359-68. doi: 10.1007 / s40273-017-0596-z.
37. Seifert J, Reinhard MA, Bleich S, et al. Psychotropic drug-induced adverse drug reactions in 462,661 psychiatric inpatients in relation to age: results from a German drug surveillance program from 1993-2016. Ann Gen Psychiatry. 2024 Nov 18;23(1):47. doi: 10.1186/s12991-024-00530-0.
Review
For citations:
Gomon Yu.M., Kolbin A.S., Lavrova V.A., Neznanov N.G. Pharmacoepidemiology of antidepressants in the Russian Federation. Real-World Data & Evidence. 2025;5(1):49-58. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-068. EDN: VZWAZD
Views:
277
Email this article 
Post a Comment 